MUSCLE-INVASIVE UROTHELIAL CARCINOMA
Clinical trials for MUSCLE-INVASIVE UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MUSCLE-INVASIVE UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for MUSCLE-INVASIVE UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise for bladder cancer patients unable to get chemo
Disease control OngoingThis early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how t…
Matched conditions: MUSCLE-INVASIVE UROTHELIAL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy aims to stop bladder cancer return after surgery
Disease control OngoingThis study tests whether adding a personalized cancer vaccine (V940) to standard immunotherapy (pembrolizumab) can prevent high-risk bladder cancer from coming back after surgery. About 230 adults with muscle-invasive bladder cancer will receive either the vaccine plus immunother…
Matched conditions: MUSCLE-INVASIVE UROTHELIAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Real-World data sought on nivolumab for bladder cancer after surgery
Knowledge-focused OngoingThis study observes 400 Japanese patients with muscle-invasive urothelial carcinoma who received nivolumab after surgery to remove their cancer. Researchers will track how long patients stay cancer-free, side effects, and how the drug is actually used in clinics. The goal is to s…
Matched conditions: MUSCLE-INVASIVE UROTHELIAL CARCINOMA
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC